Biodefense

CDX-2301

Anthrax Biodefense program

The long term goal of this project is the development of novel targeted immuotherapies against emerging infectious diseases and pathogens associated with bioterrorism. Our previous studies have documented the extremely rapid and potent immune responses elicited by vaccines that target antigens specifically to APCs. We believe that in addition to induction of rapid and robust immune responses, targeted vaccines have the potential to be safer, more easily administered, and require very low doses, resulting in a more cost-effective product. We have developed a targeted vaccine for prevention and treatment of anthrax by attaching the anthrax protective antigen to our human mannose receptor binding antibody. Vaccine efficacy is being assessed using intramuscular or nasal delivery. Successful completion of the project could potentially result in an easily administered, cost-effective vaccine that would be useful for the vaccination of individuals 1) suspected of exposure, 2) at high risk of near-term exposure, 3) and possibly after appearance of anthrax related symptoms. Such a vaccine could also greatly reduce the course of antibiotics that is currently given to potentially exposed individuals. Furthermore, this vaccine would serve as a prototype for application of this technology to other important infectious disease pathogens where a fast acting vaccine is needed.